KNRS logo

Kinarus Therapeutics Holding SWX:KNRS Stock Report

Last Price

CHF0.0042

Market Cap

CHF4.5m

7D

-12.5%

1Y

-65.0%

Updated

24 Mar, 2024

Data

Company Financials

Kinarus Therapeutics Holding AG

SWX:KNRS Stock Report

Market Cap: CHF4.5m

KNRS Stock Overview

Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases.

KNRS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Kinarus Therapeutics Holding AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kinarus Therapeutics Holding
Historical stock prices
Current Share PriceCHF0.0042
52 Week HighCHF0.013
52 Week LowCHF0.0002
Beta0
1 Month Change-34.38%
3 Month Change950.00%
1 Year Change-65.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-89.50%

Recent News & Updates

Recent updates

Shareholder Returns

KNRSCH PharmaceuticalsCH Market
7D-12.5%-0.8%-0.1%
1Y-65.0%-1.2%5.5%

Return vs Industry: KNRS underperformed the Swiss Pharmaceuticals industry which returned -1.2% over the past year.

Return vs Market: KNRS underperformed the Swiss Market which returned 5.5% over the past year.

Price Volatility

Is KNRS's price volatile compared to industry and market?
KNRS volatility
KNRS Average Weekly Movement91.1%
Pharmaceuticals Industry Average Movement3.1%
Market Average Movement3.4%
10% most volatile stocks in CH Market7.8%
10% least volatile stocks in CH Market1.7%

Stable Share Price: KNRS's share price has been volatile over the past 3 months.

Volatility Over Time: KNRS's weekly volatility has increased from 65% to 91% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aAlexander Bauschhttps://www.kinarus.com

Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.

Kinarus Therapeutics Holding AG Fundamentals Summary

How do Kinarus Therapeutics Holding's earnings and revenue compare to its market cap?
KNRS fundamental statistics
Market capCHF4.49m
Earnings (TTM)CHF0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KNRS income statement (TTM)
RevenueCHF0
Cost of RevenueCHF0
Gross ProfitCHF0
Other ExpensesCHF0
EarningsCHF0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did KNRS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.